ArticleBMC gastroenterology2026
Prognostic value of CT-defined sarcopenic obesity in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe prognostic value of sarcopenic obesity is controversial in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). This study aimed to deconstruct the sarcopenic obesity phenotype to clarify the independent prognostic impacts of sarcopenia and visceral obesity.
methodsWe retrospectively analyzed 415 patients with unresectable HCC who underwent TACE between 2009 and 2020. Skeletal muscle index (SMI) and visceral fat area (VFA) were measured from baseline CT scans at the L3 vertebra level. Sarcopenia (SMI ≤ 36.2 cm²/m² in males, ≤ 29.6 cm²/m² in females) and visceral obesity (VFA ≥ 100 cm²) were defined using Asian-specific cutoffs. Overall survival (OS) was analyzed using Kaplan-Meier and Cox proportional hazards models, with sex-stratified analysis.
resultsAmong 415 patients (72% male, median follow-up 21.4 months), sarcopenia prevalence was 34% and visceral obesity 59%. In sex-stratified analysis, sarcopenia predicted mortality in males and reduced the median OS by 11 months (14.4 vs. 25.4 months, p < 0.001), but not in females (23.4 vs. 22.8 months, p = 0.900). Visceral obesity showed no prognostic impact in either sex. In sex-stratified multivariate analysis adjusting for Child-Pugh class, tumor burden, BCLC stage, and AFP, sarcopenia remained independently associated with mortality in males (adjusted hazard ratio [HR] = 1.41, 95% CI: 1.06-1.86, p = 0.018) but not in females (adjusted HR = 0.84, 95% CI: 0.55-1.27, p = 0.404; p for interaction = 0.070), while visceral obesity and sarcopenic obesity composite showed no prognostic value in either sex.
conclusionThe sarcopenic obesity composite phenotype lacks prognostic value in TACE-treated HCC patients. Sarcopenia independently predicts mortality in males but not females, while visceral obesity shows no independent prognostic significance. Clinical risk stratification could consider sarcopenia assessment in male patients rather than composite phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.